Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and ne
Safety is an essential part of the evaluation of new medications and competing risks that occur in most clinical trials are a well identified challenge in the analysis of adverse events. Two statistical frameworks exist to consider competing risks: the cause-specific and the subdistribution framework...
New, better medications are the best and swiftest way for this country to cut down on our health care expenses. And appropriate reimbursement stimulates competition – which drives down prices. When it comes to measuring value, we must embrace a comprehensive view of cost and benefit. Choosing ...
Clinical trials of early or preventive interventions based on amyloid/tau theory and those targeting other pathophysiologies are ongoing or have been initiated. Many ongoing clinical trials on AD are focused on disease-modifying therapies (DMTs) that target the causes and can change the course of A...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
combined with subsequent optimization of leads through modern medicinal chemistry, followed by toxicology and metabolic studies and an understanding of basic pharmacokinetics, would lead to a range of new and more effective medications for those who did not respond well to the original antipsychotics, ...
Investigators will report start of other medications at every study visit. Whether participants will have serious adverse events (SAE) and adverse events of special interest (AEoSI) during the study period. AEoSI include, but are not limited to, infections, malignancies, and joint complaints or ...
Even though new drugs will help to improve the prognosis of people with DKD, it becomes more and more a challenge for physicians to choose the most beneficial medication or combination of medications for an individual patient. There is a need to evaluate the kidney-protective effects of ...
Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996–2015. J Affect Disord. 2020;276:883–9. Article CAS PubMed Google Scholar Lucas-Carrasco R. The WHO quality of life (WHOQOL) questionnaire: Spanish...
treatmenthas come a long way. With daily medication, most people with HIV can live a normal life span. But unmet needs still remain. Some people, for example, find it hard to remember to take their medicine every day. Others develop drug-resistant strains of HIV that make medications ...